专注于甲胺:其在怀孕期间及其后期的作用和安全性
Christine Newman1,2, Louise Rabbitt3,4, Adesuwa Ero5
1Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospital, Galway, Ireland. newman.christine17@gmail.com.
Drugs
|June 24, 2023
概括
甲胺是一种广泛用于治疗2型糖尿病和妊娠期糖尿病的治疗方法. 本综述考察了其有效性,副作用以及怀孕期间和之后对母亲和婴儿的长期结果.
科学领域:
- 产科和妇科 产科和妇科
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲胺是2型糖尿病的第一线治疗方法,自20世纪70年代以来,也用于妊娠糖尿病.
- 由于易于使用,成本效益和有利的副作用概况,患者接受度很高.
- 它在减少妊娠期间巨和孕产妇体重增加方面表现出有效性.
研究的目的:
- 审查孕期甲福尔的疗效和安全性.
- 分析母亲和婴儿的不良影响和长期随访.
- 为了比较甲福明与替代妊娠糖尿病治疗方法.
主要方法:
- 关于怀孕期间使用甲福明的研究文献综述.
- 分析有关母亲和胎儿结局的数据.
- 与其他妊娠糖尿病疗法进行比较研究的评估.
主要成果:
- 甲素有效地降低了宏观症和对妊娠年龄大的婴儿.
- 一些研究表明,胎儿尺寸可能会减少,妊娠年龄的婴儿可能会增加.
- 随着甲福林的使用,母亲的体重增加减少.
结论:
- 甲胺在治疗妊娠期糖尿病方面有好处,包括减少巨.
- 改变胎儿生长的潜在风险需要仔细考虑和监测.
- 综合性审查支持在怀孕期间对甲福明的临床决策.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Oral Hypoglycemic Agents: Glinides
189
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
189
Pathophysiology of Diabetes
1.0K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
210
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
210
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214


